01127nas a2200145   4500000000100000008004100001260004900042100001500091700001400106245003300120250001600153856010700169520068300276020002200959       2020                            d  bWorld Alliance for Wound and Lymphedema Care1 aLehman L F1 aVuagnat H00aHansen’s Disease (Leprosy)  a2nd Edition  uhttps://wawlc.org/fileadmin/user_upload/WAWLC/WAWLC_Lymphoedema_Report_17x24_FINAL_Electr.pdf#page=1183 aHansen’s disease (HD), also known as leprosy, is a chronic disease caused by a
slowly multiplying bacillus, Mycobacterium leprae, mainly affecting skin, periph‑
eral nerves, mucosa of the upper respiratory tract, and eyes. (1) Primary nerve
impairments and disability can be prevented or minimised when disease is diag‑
nosed early and managed adequately. (1–3) The incubation period of the disease
is about five years, but symptoms can take as long as 20 years to appear. (1) The
World Health Organization (WHO) recommends MDT (multi-drug therapy) con‑
sisting of two or three drugs: dapsone and rifampicin for all plus clofazimine for
multibacillary disease.  a978-87-971974-1-7